cyrilzakka/clinical-trials huggingface dataset:
All on Six Versus Parallel Implant Distribution for Maxillary Denture Opposing Mandibular All on Four

Thirty maxillary edentulous patients with previous mandibular All-on-4 screw retained prosthesis and their age ranged from 55 to 65 years were selected from the outpatient clinic, of prosthodontics Department, Faculty of Dentistry, Mansoura University from March 2022 to July2022 and 80% power was used to calculate patients sample according to the results of a previous study 1 which showed no significant difference was reported when comparing occlusal stability ,implant stability and periimplant soft tissue changes between different implants angulation of both groups. (Effect size=.70mm and α=.05). The power analysis was performed using the G\*Power program (version 3.1.5, Kiel, Germany)

the aim of this study is to compare between All-on-Six distributed dental implants "Anterior 4 Implant Parallel and Posterior 2 Implant Distally Tilted" versus parallel distribution supporting screw retained maxillary single denture regarding soft tissue changes around implants, implant stability and occlusal stability.

The primary outcome is to study implant stability and occlusal stability. The secondary outcome is to evaluate periimplant soft tissue changes. The null hypothesis of this study will be there is no difference between the two studied groups.All patients were informed about the proposal of this study, the line of treatment, and the need for regular and frequent recalls. Their acceptance to participate in this study was confirmed and they signed the consent form of the ethical committee of the faculty of dentistry. This study gained the approval of the ethical committee of the Faculty of Dentistry, with approval number (A05080622).

all the patients were divided randomly into two equal groups as follows Group I patients received four axially placed anterior Implants(\*General system) in lateral and first premolar region and two distally tilted 30 degree posteriorly in molar region relative to the occlusal plane supporting screw retained maxillary single denture.

Group II patients received 6 implants in parallel distribution in anterior, premolar and molar region

Eligibility Criteria:
Inclusion Criteria:

* patient with maxillary edentulous alveolar ridges.
* patient complained from insufficient retention and stability of their maxillary single denture.

Exclusion Criteria:

* medically compromised patients.
* patients with parafunctional habits.
Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male Adults

Open Label Placebo application has been shown to be effective in treatment of chronic pain (low back pain) and disease like the irritable bowel Syndrome. Data about effects on acute pain are spare.

The study investigates the effect of an open-label Placebo (substance without a medical active component) application on acute pain, evoked via a artificial pain model in healthy male volunteers. 32 healthy male volunteers are recruited.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male volunteers (American Society of Anaesthesiologist's Class I or II)
* Body mass index between 18 and 25kg/m2
* Able to understand the study and the NRS scale
* Able to give informed consent

Exclusion Criteria:

* Recreational drug abuse
* Regularly taking medication potentially interfere with pain sensation (analgesics, antihistamines and calcium and potassium channel blockers)
* Neuropathy
* Chronic pain
* Neuromuscular or psychiatric disease
* Known or suspected kidney or liver disease
Obstructive Sleep Apnea Syndrome (OSA) and Getemed

It is often clinically impossible to differentiate children with an isolated snoring from those with OSA. The diagnosis of OSA is currently based on nocturnal, laboratory-based polysomnography. This expensive examination is poorly accessible due to appointments delays at hospital.

Our study is designed to compare the characteristics of a home polysomnography versus standard polysomnography for the diagnosis of pediatric OSA.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects, aged 2 to 6 years old, requiring a polysomnography or admitted for intense snoring or suspected sleep apnea
* Parents must have signed the inform consent form and be covered by the National Health Insurance Program.

Exclusion Criteria:

* Parents opposed to the study.
Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis

In this study, the researchers want to find out how patients who have ultrafiltration (removal of excess fluid) 6 times a week and twice-weekly dialysis (removal of excess fluid and waste products) do in terms of their blood pressure and weight. The researchers believe that maintaining patients at their estimated target weight throughout the week using daily ultrafiltration will reduce their blood pressure to levels shown in other similar studies. Such a reduction in blood pressure may reduce the incidence of cerebral vascular disease, peripheral vascular disease, coronary artery disease, and congestive heart failure. The researchers also believe that patients' quality of life will improve while they are undergoing daily ultrafiltration.

Studies show that more frequent dialysis treatments result in fewer symptoms for patients. The patients feel better and avoid the weight gains and symptoms that patients have on three times a week dialysis. In addition, their blood lab results are better controlled, requiring less medication.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than or equal to 18 years and less than or equal to 80 years
* Stable three treatments per week dialysis schedule for at least three months prior to beginning the study
* Residual renal clearance \<1.5ml/min per 35L of urea volume
* Pre-dialysis serum sodium levels of greater than 136 mEq/L

Exclusion Criteria:

* Non-compliance with hemodialysis treatments--defined as missing more than 1 treatment over the 3 month period prior to the study
* Unable to verbally communicate in English or Spanish
* Current requirement for hemodialysis more than three times per week due to medical comorbidity (including fourth session for ultrafiltration)
* Currently on daily or nocturnal hemodialysis, or less than 3 months since discontinued such treatment
* Expected geographic unavailability at dialysis center during any phase of the trial
* Less than 3 months since the patient returned after acute rejection resulting in allograft failure
* Currently in acute care or chronic care hospital
* Pregnancy
* Current involvement in any non-observational trial
* Unable or unwilling to follow the study protocol for any reason (including mental incompetence)
* Unable or unwilling to provide informed consent or sign IRB-approved consent form
* Pace maker, implantable pump, artificial joint
* Amputation of a limb
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.


Eligibility Criteria:
Inclusion Criteria:

* Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled
* Subjects should be on a stable regimen of one or a maximum of two other antiepileptic drugs (AEDs) for at least 2 weeks prior to Visit 1
* Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70
* Subject and parent/guardian should be fluent in English

Exclusion Criteria:

* Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication
* Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1
* Subject has seizures too close together to accurately count
* Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders
Clinical Study of the Topcon Pachymeter TRK-3 to Evaluate Agreement and Precision

Agreement and Precision of corneal thickness measurement (pachymetry) function of the test device TRK-3 and the predicate device SP-1P will be evaluated in volunteers, and safety will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

1. Individuals who gave written informed consent to participate in the clinical trial by their free will.
2. Individuals who aged 20 years or older at the time of informed consent
3. Individuals who were deemed eligible for the study by the investigator for screening prior to enrollment.
4. Subjects who are able to comply with compliance items during participation in the clinical trial, undergo medical examination and examination specified in the protocol, and report subjective symptoms, etc.

Exclusion Criteria:

1. Individuals with ocular diseases that may affect corneal thickness measurement (blindness, corneal perforation, bullous keratopathy, nystagmus, etc.) or who have a history of ocular diseases and are considered by the investigator to be ineligible for participation in the study.
2. Individuals who have or are suspected of suffering from ocular or systemic infections.
3. Other persons who are judged by the investigator to be unfavorable candidates for the study.
Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation

A positive Anti-Neutrophil Cytoplasm Antibody (ANCA) test administered to patients with a high probability for vasculitis has high sensitivity and specificity for vasculitis. A positive ANCA test result in those patients who do not have a high probability for vasculitis requires extensive follow-up because those patients eventually present with malignancy or other inflammatory diseases. The investigators wish to investigate the correlation between the differing levels of positive ANCA tests and their relationship to vasculitis, malignancy and inflammatory diseases.


Eligibility Criteria:
Inclusion Criteria:

* Patients with borderline positive ANCA test results

Exclusion Criteria:

* Pregnant
Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp. It would be important to have a maintenance treatment for severe forms of seborrheic dermatitis witch is both effective and relatively well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack treatment and reduce the use of topical steroids.


Eligibility Criteria:
Inclusion Criteria:

* in Phase 1: Attack Treatment (open)

  1. over the age of eighteen patient,
  2. Seborrheic dermatitis Severe,
  3. participation with an informed consent,
  4. Women of childbearing age in effective contraception for the duration of the study or postmenopausal women.
* in Phase 2: Phase 2: "Randomization" (blind)

  1. Patient achieved a complete or almost complete clinical remission after the initial treatment,
  2. known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressive therapy or biotherapy,
  3. patient taking regular systemic corticosteroids at a dose\> 20 mg / day
  4. erythematous lesions with topography other than the face and evocative scalp psoriasis (elbows, knees ...), by referring to the possibility that the facial lesions correspond to lesions sebopsoriasis,
  5. woman pregnant, nursing or in childbearing potential without effective contraception,
  6. man wishing to have a child during the study period,
  7. Ultra Violet (UV) phototherapy or usual realization of UV sessions aesthetic purposes,
  8. Seborrheic dermatitis symptomatic of an underlying disease known or revealing
  9. history of cancer or lymphoma,
  10. progressive cancer or lymphoma,
  11. Seborrheic dermatitis exclusively affecting the scalp,
  12. known allergy to one-component products study ,
  13. malnourished patient or sick history of chronic pancreatitis by a suspect to deficiency dermatitis,
  14. participation in a clinical trial on the Seborrheic dermatitis in the previous 90 days,
  15. patient with lesions considered potentially malignant or pre-cancerous,
  16. patient with abnormal skin barrier.

Exclusion Criteria:

* in Phase 1: Attack Treatment (open)

  1) Patient had already been treated with Protopic ® for Seborrheic Dermatitis,
* Phase 2: "Randomization" (blind) 1) Patient with no complete or almost complete clinical remission after the initial treatment,
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm\^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24). The study included a 5-week, open-label, randomized period followed by a 20-week open-label extension period. Patients were randomized to either an immediate switch from donepezil to rivastigmine patch formulation or to a switch to rivastigmine patch formulation following a 7-day withdrawal period.


Eligibility Criteria:
Inclusion Criteria:

* Be at least 50 years of age;
* Have a diagnosis of probable Alzheimer's Disease;
* Have an MMSE score of \> or = 10 and \< or = 24;
* Must have a caregiver who is able to attend all study visits;
* Have received continuous treatment with donepezil for at least 6 months prior to screening, and received a stable dose of 5 mg/day or 10 mg/day for at least the last 3 of these 6 months.

Exclusion Criteria:

* Have an advanced, severe, progressive, or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient at special risk;
* Have a history of malignancy of any organ system, treated or untreated, within the past 5 years;
* Have a history within the past year or current diagnosis of cerebrovascular disease;
* Have a current diagnosis of severe or unstable cardiovascular disease; Have a history of myocardial infarction (MI) in the last six months;
* Severe or unstable respiratory conditions (e.g., severe asthma , severe pulmonary (lung) disease);
* Digestive problems related to peptic ulcer;
* Urinary obstruction or current severe urinary tract infection;
* Abnormal thyroid function tests;
* Low folate or Vitamin B12;
* Have a disability that may prevent the patient from completing all study requirements;
* Have a current diagnosis of an active skin lesion/disorder that would prevent adhesion of a patch;

Other protocol-defined inclusion/exclusion criteria may apply
Effects of Lateral Femoral Cutaneous Nerve Mobilization With and Without Muscle Energy Techniques in Pregnant Females

The rationale of this study is to provide empirical evidence regarding the efficacy and safety of neural mobilization in pregnant women with meralgia paresthetica. By investigating the potential benefits of this intervention, healthcare professionals can make informed decisions about incorporating neural mobilization into the management of this condition during pregnancy. Focusing on the impact of neural mobilization and muscle energy techniques on both neuropathic pain and quality of life aligns with a patient-centered approach to care. The goal is not only to reduce symptoms but also to enhance overall well-being and functional capacity

The literature gap of the study is that upto our knowledge, there is little or no evidence found in previous researches on the combined effects of lateral femoral cutaneous nerve mobilization in combination with MET in pregnant females. Secondly no quantitative measurement as range of motion with goniometer has been yet studied

Eligibility Criteria:
Inclusion Criteria:

* Age ranges from 18 to 40 years
* Body mass index ≥25kg/m2.
* Pregnant females in third trimester diagnosed with myalgia paraesthetica.
* Multigravida pregnant females
* Patients will be screened through Prone Knee Bend (PKB) test for femoral nerve compression.
* Positive pelvic compression test(1)

Exclusion Criteria:

* Those having other entrapment syndromes or radicular symptoms
* Motor weakness
* Having a history or ongoing cancerous proliferation
* Active infection
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial

Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.

Acute renal failure (ARF) is a frequent complication in sepsis, in nearly to 50% of the cases, and the mortality rate is higher, compare to patients with ARF alone (70% vs 45%). Clinical and experimental studies demonstrated the key role of apoptosis, or programmed cell death, in the induction of tubular and glomerular injury in the course of sepsis. Indeed, it has been shown that inflammatory cytokines and lipopolysaccharide (LPS) cause renal tubular cell apoptosis via Fas- and caspase-mediated pathways. In addition, LPS is able to alter the normal expression pattern of sodium, urea and glucose renal transporters and to modulate tubular polarity by changing the expression of tight junction proteins with consequent back-leakage of tubular fluid in the interstitial spaces and enhancement of the inflammatory process. Therefore a novel extracorporeal therapy to remove circulating LPS, using the Polymyxin-B fiber (PMX-B) cartridge was developed. The PMX-B cartridge is an extracorporeal hemoperfusion device and consists of a polystyrene-based, fibrous adsorbent on which the polymyxin B antibiotic is covalently immobilized as a ligand to adsorb endotoxin.

Aim of this study is to verify whether the removal of LPS, using the PMX-B hemoperfusion system, protects from acute renal failure, reduces the need for Renal Replacement Therapy (RRT) and consequently improves the outcome in severe sepsis from gram negative infection.

Eligibility Criteria:
Inclusion Criteria:

* Endotoxemia associated to severe sepsis

Exclusion Criteria:

* Age \< 18 years old
* Organ transplantation
* Hemorrhagic shock
* Thrombophilia
* Chronic renal failure
* Cardiogenic shock
* APACHE II score \> 30
* Lack of consent
Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy

While the gold standard of treatment in invasive bladder cancer is surgical removal of the bladder, it is well accepted that a reasonable alternative is an organ preserving approach. Bladder preservation can be achieved in patients with radiotherapy alone or together with concurrent chemotherapy. This clinical trial will assess the potential of intensity modulated radiation therapy (IMRT) delivered using helical tomotherapy to reduce radiation-induced gastrointestinal toxicity and increase the accuracy of bladder cancer irradiation.

Patients opting for bladder conservation in Ottawa are currently treated using intra-arterial cisplatin and concurrent radiotherapy using 3D-Conformal radiotherapy. It has been recently reported that while combination chemotherapy with local therapy (surgery or radiation) does modestly increase survival, greater toxicity results. As a precursor to the integration of gemcitabine in the standard chemotherapy regimen at our centre, the current clinical trial is designed to determine if a novel approach to the delivery of intensity modulated radiotherapy (IMRT), namely Helical Tomotherapy, will decrease the toxicity of standard chemoradiation. Chemoradiation will be administered as follows: 3 courses Intra-Arterial Cisplatin 90mg/m2 every 3 weeks and radical radiation delivered as IMRT for a total dose of 60 Gy in 30 daily fractions of 2 Gy per day M-F starting day 15.

Eligibility Criteria:
Inclusion Criteria:

1. A pathological diagnosis of pure or predominantly transitional cell bladder carcinoma
2. Adequate Hematology and biochemistry parameters
3. Invasive or treatment refractory non-invasive transitional cell bladder carcinoma OR operable patients who prefer bladder preservation OR inoperable patients.
4. No metastases on CT scan of chest

Exclusion Criteria:

1. Patient with contraindication to radical radiotherapy including inflammatory bowel disease or significant irritative bladder symptoms
2. Contraindication to internal iliac arterial catheterization
3. Prior pelvic radiotherapy for other malignancies
4. Prior cytotoxic chemotherapy excepting intravesical agents
An Exploratory Investigation to Identify if Dame Product's "DLM" Works to Improve Sexual Desire and Mood in Females

This is a single-group, non-randomized, non-controlled, open-label observational trial to study and evaluate the efficacy of a commercial dietary supplement, called "DLM" ("test product"). It is hypothesized that the test product, which is designed as an edible gummy, will present a favorable result to increase sexual desire and improve mood.


Eligibility Criteria:
Inclusion Criteria:

* Females between 24-65 of age
* Must be in good health (don't report any medical conditions asked in the screening questionnaire)
* Experience sexuality-related personal distress (established in an online-screening questionnaire)
* Experience a regular menstrual cycle
* In the subject's opinion, previously experienced "normal sexual desire"
* Self-reported stress in their daily lives
* My present with self-reported anxiety
* Trouble being present in the moment
* Consider themselves as being busy all the time

Exclusion Criteria:

* Current urinary or vaginal infection
* Vaginal prolapse and any other disease that could interfere with the study conduction and participation
* Diagnosis of depression
* Diagnosis of anxiety
* Currently experiencing significant symptoms of a mental disorder that might interfere with study participation (e.g. eating disorder, obsessive-compulsive disorder, posttraumatic stress syndrome, bipolar disorder)
* Current substance abuse disorder
* Diagnosis of an autoimmune disease, such as multiples sclerosis and rheumatoid arthritis
* Self-reported or diagnosed hypotension (BP \< 90 over 60)
* Is currently using, or has used any of the following types of medication within 6 months of screening:

Any for of antidepressants; Mood stabilizers Benzodiazepines ("tranquillizers") Cognitive enhancers or stimulants (e.g. Adderall) The following contraception: Hormonal combination birth control pill; hormonal progesterone-only birth control pill; birth control patch; NuvaRing; Nexplanon Taking insulin or other diabetes medication

* Currently, or in the past 6 months, undergoing hormone therapy
* Any medical condition that is unstable or uncontrolled
* A history of sexual trauma or abuse
* Females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding